Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

What Was Tested

The paper reports a study of Insulin Glargine and NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

According to the abstract, 518 subjects were involved.

PubMed indexes the participants as middle-aged adults, both men and women.

A total of 518 subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control were randomized to receive insulin glargine (HOE 901) once daily (n = 259) or NPH insulin once or twice daily in = 259) for 28 weeks in an open-label, multicenter trial.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Insulin Glargine study over different clinics and patient groups.

The methods mention a period of 28 weeks.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Mass Index, Circadian Rhythm, Diabetes Mellitus, Type 2, Fasting, Glycated Hemoglobin and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Glargine and NPH Insulin (isophane) in 518 subjects over 28 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page and the NPH Insulin (isophane) compound page.